Downstream Issues Still Beset Production
To Protect the Bottom Line, Biomanufacturers Invest in Downstream Purification Technology
GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
10 Takeover Targets of 2016
Which Biopharmas Do Wall Street Watchers View As Top Buyout Candidates?
Drug developers have been trying for years, often in failure, to develop and market a noninjectable form of insulin for diabetes. Recently, however, progress has been made on several fronts. (Learn more about that progress here.) Do you think we are coming close to the point when a noninjectable form of insulin will reach the market?